Dow Pharmaceutical Sciences
15
0
0
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
53%
8 trials in Phase 3/4
36%
5 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Role: collaborator
Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis
Role: collaborator
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Role: collaborator
Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
Role: collaborator
Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne
Role: collaborator
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Role: lead
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
Role: lead
Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis
Role: lead
The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis
Role: lead
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis
Role: lead
A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD)
Role: collaborator
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
Role: lead
A Clinical Study Evaluating the Safety and Efficacy of IDP-115 in Patients With Rosacea
Role: lead
A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
Role: lead
A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
Role: lead
All 15 trials loaded